Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Ad5-nCoV Vaccine for COVID-19 in Russia
NCT04540419Phase 3Completed
- Sponsor
- Petrovax Pharm
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad5-nCoV with Placebo (2 arms). Primary endpoint: Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion at Day 28. Started Sep 2020; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04540419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540419.